CytoAgents Receives Fourth Grant From National Institutes of Health to Advance Research on Cytokine Release Syndrome

PITTSBURGH–(BUSINESS WIRE)–CytoAgents, Inc., a clinical-stage biotechnology company developing a safe and effective preventative treatment for cytokine release syndrome (CRS) and the neurotoxicity immune effector cell-associated neurotoxicity syndrome (ICANS), announced today that it has been awarded a $2.25 million National Institutes of Health (NIH) grant, the fourth NIH grant totaling $7.85 million in five years. Read More>>